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Abstract
Community-acquired pneumonia (CAP) remains a common 
diagnosis requiring hospital admission and a leading cause 
of death worldwide. No local guideline is currently available 
for the management of CAP. Our aim was to evaluate current 
practices in the management of CAP at Mater Dei Hospital, 
Malta. In this prospective study we looked at all adult patients 
admitted with CAP in winter and summer (105 consecutive days 
for both seasons). Data collected and analysed included: basic 
patient demographics; symptoms at presentation; antibiotics 
prescribed and time of administration; co-morbidities; CURB65; 
blood oxygenation levels; admission plan; length of stay and 
follow-up; length of stay, follow-up chest radiography and death 
within 30 days from hospital admission. Of note the average time 
to first dose antibiotic was 7 hours 48 minutes (range 2 hours 13 
minutes – 14 hours 17 minutes). A total of 178 patients (50.1%) 
were admitted with CURB65 scores of 0 (n=99) and 1 (n=86). 
Most of these could have been discharged and managed in the 
community with significant impact on hospital bed occupancy. 
Eventual standardisation of acute management of CAP by the 
set-up of a local guideline will improve outcome and reduce 
hospital bed occupancy.
Introduction
Community-acquired pneumonia (CAP) is a common and 
potentially life threatening infectious disease with significant 
impact on patient morbidity and mortality as well as hospital 
resources. According to population based studies, the annual 
incidence rate of radiologically proven CAP in adults varies 
between 2.6 to 13.4 per 1000 inhabitants, with an increased 
incidence in males and at the extreme ages of life.1 Up to 50% 
are reported to require hospital admission. In 2007, 1.2 million 
people in the USA. were hospitalised with pneumonia.2 Critical 
care admissions with CAP vary from 5% in the British Thoracic 
Society (BTS) multicentre study3 to 10% in a Spanish study.4
Globally, pneumonia causes more deaths than any other 
infectious disease. In 2007 more than 52,000 people died from 
the disease in the USA.2 Mortality rates in hospitalised patients 
ranges from 5-15% in various developed countries.1 Patients 
requiring intensive care have a mortality of up to 55%.5 Mortality 
increases with age and in the presence of co-morbidities.6 The 
CURB65 score (confusion; urea >7mmol/L; respiratory rate ≥ 30 
breaths/min; blood pressure <90 mmHg systolic or ≤ 60mmHg 
diastolic; aged >65 years old) is a verified mortality prediction 
tool adopted by the BTS to assess the severity of CAP. 
The management of CAP may vary both within and in 
between countries for a number of reasons including different 
lung pathogens, in or out-patient management, caring physician, 
antibiotic availability and different health-care systems.7 
For this reason several guidelines have been published by 
various international societies to ensure standardisation in 
management. 
The aim of this study was to evaluate current practices in 
the management of CAP in the Accident and Emergency and 
Internal Medicine departments at Mater Dei Hospital, Malta.
Methods
CAP was defined as an acute respiratory illness acquired 
outside hospital with characteristic symptoms and signs 
associated with the appearance of new radiographic infiltrates 
on chest radiography. Patients from nursing homes and those 
with a diagnosis of aspiration pneumonia, tuberculosis or 
doubtful initial radiographic appearances were excluded. All 
adult patients (above 16 years) with CAP admitted to Mater 
Dei Hospital, Malta were included in a prospective study. The 
two periods studied were: December 1, 2008 to March 15, 2009 
(winter) and June 1, 2009 to September 13, 2009 (summer). 
The picture archiving and communication systems 
(PACS) system was used to review radiological findings. 
*corresponding author
Malta Medical Journal    Volume 24   Issue 02   2012 7
Admission and clinical data were collected from the patients’ 
medical case notes. The data collected included: symptoms at 
presentation; antibiotics prescribed and time of administration; 
co-morbidities; CURB65; blood oxygenation levels (oxygen 
saturation and/or arterial partial pressure of oxygen); admission 
plan; length of stay (LOS), follow-up chest radiography and 
death within 30 days from hospital admission. 
The CURB65 score was used to assess severity on 
admission.8 A co-morbidity score was devised to include the 
following risk factors: smoking, diabetes mellitus, chronic 
kidney disease, cardiovascular disease, respiratory disease 
and immunosuppression (malignancy, HIV, patients on long-
term steroids or immunosuppressants). Each co-morbidity 
was a given a score of 1. The total score ranged from 0 to a 
maximum of 6. Ethical approval was obtained from the Malta 
University Research Ethics Committee after all consultants in 
the department of medicine gave their written consent.
Statistical analysis
The data were analysed using Statistical Package for Social 
Sciences (SPSS) version 16.0. We used chi-square to analyse 
associations between categorical variables and t-test for 
continuous variables.  
Results
Incidence and demography
A total of 355 patients with CAP were included during the 
study periods: 193 and 162 patients during winter and summer 
respectively. This gives an annual inpatient incidence rate of 
1.62 cases per 1,000 inhabitants (95%CI 1.42 to 1.82). The mean 
daily number of general medical admissions was 46, of which 
1.7 were admitted with CAP. The mean age was 65 (range 16-
95). Sex distribution was 182 males and 173 females. Twenty 
patients (5.6%) required ICU care and 24 (6.8%) were admitted 
to a high dependency medical ward. 
Symptoms at presentation
The two main presenting symptoms were cough (75.8%) 
and fever (66.2%), followed by shortness of breath (54.4%) and 
sputum expectoration (53.5%). Pleuritic chest pain was present 
in only 16.1%. Most patients had more than one symptom at 
presentation (Figure 1). 
Antibiotic use
Thirty one percent of admitted patients (n=110) had received 
at least one dose of antibiotic at home prior to hospitalisation. The 
main antibiotic combination prescribed in hospital was intravenous 
cefuroxime and oral clarithromycin (38.6%, n=137), followed by 
intravenous co-amoxiclav and oral clarithromycin (13.5%, n=48). 
Monotherapy with co-amoxiclav, cefuroxime or clarithromycin 
was prescribed in 6.8% (n=24). Fluoroquinolone monotherapy 
was prescribed in 10.3% (n=37). More potent antibiotics were 
prescribed in 30.8% (n=109), of whom 26.1% (n=29) had no 
co-morbidities. There was a change in the original antibiotic 
prescription in 57.2% throughout the admission (n=203). 
The average time to first dose antibiotic was 7 hours 48 
minutes (range 2 hours 13 minutes – 14 hours 17 minutes). There 
was 73.2% (n = 260) of the whole cohort who received antibiotics 
outside the four-hour target. From the deceased patients, 75% 
(n = 39) had received their first antibiotic dose after four hours 
(Figure 2). The average total antibiotic treatment duration was 
7.2 days.
Co-morbidity score
The mean co-morbidity score was 1.8. This increased to 2.4 
in the deceased patients (p = 0.049). 
CURB65
The CURB65 score was used to assess severity on admission. 
In the study population 52% (n=184) of admissions scored 
CURB65 of 0 (28%, n=99) or 1 (24%, n=85). The most common 
CURB65 score at presentation was 2 with 110 (31%) patients. 
Twelve percent (n=43) and 5% (n=18) had a CURB65 score of 
3 and 4 respectively.
Increasing CURB65 scores showed positive correlation with 
30-day mortality in both seasons. Patients admitted during 
the winter period with a CURB65 score of 1, 2 and 4, had a 1.7, 
1.4 and 1.6 increased risk of death within 30 days respectively, 
despite similar co-morbidities (Figure 3). 
Figure 1: Symptoms at presentation
Figure 2: Percentage of recovered vs deceased in 
relation to target time to antibiotic administration
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Oxygen prescription
Oxygen saturations were assessed with pulse oximetry and/
or arterial blood gas sampling. Oxygen saturation on air was 
measured in 85.1% (n=302) patients and on oxygen in 39.4% 
(n=140). Oxygen was prescribed with a PaO2 of ≤60mmHg in 
52.4% (n=186). 
Further management 
Blood cultures and sputum cultures were requested in 
47.1% (n=167) and 60.8% (n=216) respectively. C-reactive 
protein (CRP) was taken in 15.8% (n=56). Chest physiotherapy 
was requested in 54.1% (n=192). Thrombo-prophylaxis was 
prescribed in 29.2% (n=104) (Figure 4). 
Follow up chest radiography
A chest radiograph was repeated during admission in 16.3% 
(n=58) and after discharge in 19.2% (n=68). This was repeated 
in 8.7% (n=31) both during admission and upon discharge. No 
follow-up chest radiograph was done in 67.3% (n=204).
Outcome: 30-day mortality
The average 30-day mortality for the whole population 
under study was 14.6% (n=52). There was a difference between 
the winter and summer cohorts: 17.6% (n=34) versus 11.1% 
(n=18) respectively (p=0.085). The mean age of the deceased 
was 78 years (range 51-95). Patients admitted to ICU had 15% 
mortality (n=3) and all died in winter. High dependency medical 
ward admissions had 25% mortality: 36.4% (n=4) winter, 15.4% 
(n=2) summer.
Respiratory/Infectious Disease firms versus 
General Medical firms
General medical firms admitted 56.3% (n=200) of patients 
and respiratory and infectious disease firms admitted 43.7% 
(n=155). An independent-sample t-test was conducted to 
compare length of hospital stays (LOS) between General Medical 
firms and Respiratory firms. There was no significant difference 
for General Medical (M = 7.96, SD = 6.79) and Respiratory and 
Infectious Disease firms (M = 7.40, SD = 5.89; t (354) = 0.83, 
p=0.408, two-tailed). The magnitude of the differences in the 
means (mean difference = 0.56, 95% CI: -0.77 to 1.89) was very 
small (eta-squared = 0.0006). General medical firms had a 30-
day mortality of 15.5% whilst respiratory and infectious disease 
firms had 13.6%. 
Discussion
CAP remains a common presentation in the A&E department 
of every hospital. Decisions whether hospital or outpatient 
management is most appropriate are important in determining 
outcome, hospital stay and bed occupancy.9 In May 2005 
the European Respiratory Society in collaboration with the 
European Society of Clinical Microbiology and Infectious 
Diseases (ESCMID) published new guidelines for the 
management of adult lower respiratory tract infections.10
The incidence of CAP is very variable in most European 
countries ranging from 11 per 1000 in Finland11 to 1.6 per 1000 
in Spain and Italy.12 For the period under study, the incidence 
rate was 1.62 per 1000 which is similar to neighbouring 
Mediterranean countries. This excludes patients managed in 
the community by general practitioners.
In the USA there were 17.3 deaths per 100,000 with an in-
patent mortality of 5.4% in 2006.2 The local 30-day mortality 
of 14.6% was relatively high when compared to other European 
countries, however in a recent study the 30-day mortality in a 
UK GP cohort was 18.5% in the community.13 The most widely 
studied scoring systems are the CURB65 and the Pneumonia 
Severity Index (PSI). Each has its advantages and limitations 
with the CURB65 easily identifying more severely ill patients and 
the PSI identifying low mortality risk patients. The limitation 
of these prognostic tools includes their variable utility in 
stratifying risk in the elderly, associated co-morbidities and 
social factors. The use of such scoring systems, combined 
with clinical judgement is crucial for determining the need for 
hospitalisation.10 This was clearly demonstrated in this study. 
Mortality remains high in CURB65 score of 2 or more. These 
patients will require hospitalisation, intensive treatment and 
Figure 3: Seasonal 30-day mortality in relation to 
CURB65 +
Figure 4: Further management
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monitoring. A total of 178 patients (50.1%) were admitted with 
CURB65 scores of 0 (n=99) and 1 (n=86). Most could have been 
discharged and managed in the community with significant 
impact on hospital bed occupancy. This study shows a 1.7-
fold increased risk of 30-day mortality in winter. This may be 
due to: more aggressive pathogens, later presentation, longer 
waiting times, time to effective treatment and inpatient care in 
a busy hospital. It is difficult to say which is the most important 
contributing factor, but all could play a role. 
The antibiotic choice should be guided by illness severity, 
patient age, co-morbidities, clinical presentation, epidemiology, 
previous antibiotic exposure and local antibiotic resistance.14 
Antibiotic choice and time to first dose of administration remain 
issues of discussion.15 International guidelines currently aim for 
administration within four to six hours of admission, which was 
not achieved in our hospital. This was due to long waiting times 
and lack of antibiotic access within our A&E department, which 
were then administered on the wards. Blood cultures and waiting 
for the next scheduled drug round also delayed administration. 
The most commonly prescribed combination was cefuroxime 
and clarithromycin. Respiratory fluoroquinolones were 
prescribed mostly in patients with penicillin allergy. Locally 
almost 30% of Streptococcus pneumoniae strains are resistant 
to macrolides,16 however these antibiotics cover atypical 
organisms. Appropriate and judicious antibiotic use should 
be guided by local sensitivity and resistance patterns keeping 
in mind tolerability and toxicity in each individual patient. 
Treatment directed towards particular pathogens suspected 
clinically is highly commendable. 
The duration of antibiotic treatment is usually 7 to 10 
days, except for intracellular pathogens (Legionella sp.) where 
more prolonged treatment is necessary.17 The current trend 
is to further shorten antibiotic treatment.18 Switching from 
intravenous to oral treatment depends on clinical resolution 
and ability to tolerate oral intake. This allows earlier hospital 
discharge reducing costs and risk of hospital-acquired infections. 
There is considerable variability in LOS between hospitals 
reflecting variations in clinical practice preferences, hospital 
characteristics and patient characteristics and attitudes.19 The 
mean LOS varies in many countries from 7 days in the USA20 to 
11.7 days in Spain.1 Our local mean LOS was 7.7 days.
The BTS states that all patients should receive appropriate 
oxygen therapy with the aim of maintaining PaO2 >8 kPa and 
SaO2 >92%. Oxygenation levels should be assessed by pulse 
oximetry, followed by arterial blood gas analysis if oxygen 
saturation is <92% and in patients with chronic obstructive 
lung disease. Only half of the patients in this study were 
prescribed appropriate oxygen therapy. Oxygen therapy should 
be clearly prescribed in the treatment chart including flow rate, 
concentration and mask type. 
A number of studies have questioned the clinical value and 
cost-effectiveness of routine blood cultures.21 Many clinicians 
agree that these are important in severely ill patients (CURB65 
≥2 or PSI IV, V) and if a specific risk factor for pathogens 
resistant to empirical therapy is present. 
Sputum cultures are another controversial laboratory tool. 
In our study these were requested in 60.8%, however the actual 
number reaching the laboratory was much less and most were 
after first antibiotic administration. Samples should be sent to 
the laboratory in moderate to severe CAP and in those failing 
to improve clinically. The Infectious Disease Society of America 
(IDSA) and the Canadian Infectious Disease Society/Canadian 
Thoracic Society (CIDS/CTS) recommend routine sputum 
analysis for all inpatients with CAP, while the American Thoracic 
Society (ATS) recommends this only if a drug-resistant pathogen 
or an organism not covered by usual empiric therapy is suspected.
 CRP whose initial description was based on pneumonia 
patients is useful for establishing the severity of CAP.22 Seppa et al. 
reported that a CRP level >100 mg/L is a marker independently 
associated with higher risk of death.23 A Scandinavian study 
observed that patients with higher CRP levels had longer fever 
duration, longer hospital stays and fewer patients had recovered 
clinically or radiographically at 8 weeks follow-up.24 Failure of 
CRP to fall by 50% or more at day 4, independent of admission 
CRP level, was shown to be associated with increased 30-day 
mortality and need for mechanical ventilation and/or inotropic 
support and complicated pneumonia.25 In our study CRP was 
only taken in 15.8% mostly on the day after admission. Another 
biomarker gaining interest is procalcitonin (PCT). PCT rises in 
response to systemic inflammation associated with infection and 
correlates well with pneumonia severity.26,27 A low PCT (<0.228 
ng/ml) has a high negative predictive value for mortality from 
CAP when compared with the CRB65 score.26
Chest physiotherapy has been widely used as a routine 
adjunctive therapy for pneumonia. A review of six randomised 
controlled trials concluded that chest physiotherapy has no 
benefit in reducing LOS, and mortality during the acute phase 
of CAP.28
Guidelines for prevention of venous thromboembolism 
recognise pneumonia as a risk factor causing significant 
morbidity and mortality. Decreased mobility, dehydration and 
co-morbidities increase this risk further. This study reflects local 
inadequacy in prescribing thromboprophylaxis.
According to the BTS, the chest radiograph need not be 
repeated prior to hospital discharge in those with a satisfactory 
clinical recovery. A chest radiograph should be arranged after 
about 6 weeks for patients with persistence of symptoms or 
physical signs or those at higher risk of malignancy (smokers 
and age >50 years). Our study shows that most of the discharged 
patients (n=204) were not followed up with a chest radiograph. 
Conclusion
Standardisation of acute management of CAP will improve 
outcome and reduce hospital bed occupancy. A clear delineation 
of hospital admission criteria on basis of severity scores is 
essential as a significant number of patients may be managed in 
the community with the establishment of a general practitioner/
nurse-led home treatment programme. Timely and appropriate 
antibiotics, supportive treatment and laboratory tools may 
optimise inpatient management. Admission under respiratory 
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or infectious disease firms may also improve outcome. Clinical 
improvement together with radiology and laboratory tools 
reflect resolution of CAP and hence decision on discharge. 
Follow up with a chest radiograph in six weeks is often necessary. 
The set up of a local guideline on the management of CAP is 
pivotal for providing excellence in clinical care of these patients.
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